SCHEMBL2582633

SCHEMBL2582633

NNC(=O)C1CCC(n2cccn2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.41
PDK1 Q15118 1/20 0.40
PDK2 Q15119 1/20 0.40
HCAR2 Q8TDS4 1/20 0.37
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
HPGD P15428 2/20 0.33
USP9X Q93008 1/20 0.33
CHKA P35790 1/20 0.32
ROCK2 O75116 3/20 0.31
ROCK1 Q13464 3/20 0.31
PKN2 Q16513 3/20 0.31
RPS6KA5 O75582 2/20 0.31
LRRK2 Q5S007 2/20 0.31
TP53 P04637 2/20 0.31
CYP3A4 P08684 2/20 0.31
CHUK O15111 1/20 0.31
PRKD3 O94806 1/20 0.31
CDK1 P06493 1/20 0.31
CDK2 P24941 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2582631 1.00 EPHX2 (0.41) EPHX2PDK1PDK2HCAR2ADORA2A
SCHEMBL2585926 1.00 EPHX2 (0.41) EPHX2PDK1PDK2HCAR2ADORA2A
SCHEMBL12181026 0.82 EPHX2 (0.39) EPHX2PDK1PDK2HCAR2ADORA2A
SCHEMBL2579447 0.80 EPHX2 (0.44) EPHX2PDK1PDK2HCAR2ADORA2A
SCHEMBL2583238 0.80 EPHX2 (0.44) EPHX2PDK1PDK2HCAR2ADORA2A
SCHEMBL2579445 0.80 EPHX2 (0.44) EPHX2PDK1PDK2HCAR2ADORA2A
SCHEMBL29159598 0.78 EPHX2 (0.41) EPHX2PDK1PDK2HCAR2HPGD
SCHEMBL57030 0.77
Hydrochloric Acid SCHEMBL28314935 0.75
SCHEMBL20648702 0.74 EPHX2 (0.36) EPHX2PDK1PDK2HCAR2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2569319-B1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES HOFFMANN LA ROCHE (CH) 2014-09-24 EP disclosed
US-8513238-B2 Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes HOFFMANN-LA ROCHE INC. (US) 2013-08-20 US disclosed
EP-2569319-A1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES F.HOFFMANN-LA ROCHE AG (CH) 2013-03-20 EP disclosed
WO-2011141396-A1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES F. HOFFMANN-LA ROCHE AG (CH) 2011-11-17 WO disclosed
US-20110275801-A1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES HOFFMANN-LA ROCHE, INC. 2011-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275801-A1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AVPR1A, AVPR1B, OXTR EPHX2 3670/4885PDK1 2348/4885PDK2 2941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.